Boston Scientific vs HCA Healthcare
Side-by-side comparison of AI visibility scores, market position, and capabilities
Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.
About
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
Largest US for-profit hospital network with ~190 hospitals; $70.7B FY2024 revenue; AI clinical decision support reducing preventable mortality; Sun Belt demographics advantage; NYSE: HCA.
About
HCA Healthcare is the largest for-profit hospital system in the United States, founded in 1968 by Jack Massey, Dr. Thomas Frist Sr., and Dr. Thomas Frist Jr. in Nashville, Tennessee, where it remains headquartered and trades on NYSE (HCA). The company operates approximately 190 hospitals and 2,400 ambulatory care sites—including surgery centers, physician clinics, and urgent care facilities—across 20 U.S. states and the United Kingdom, serving over 37 million patients annually. For FY2024, HCA generated approximately $70.7 billion in revenues under CEO Samuel Hazen, continuing a multi-year growth trajectory driven by hospital volume recovery, acuity mix improvement, and strategic investments in ambulatory care that intercept patients in lower-cost settings before they require inpatient hospitalization.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.